Home / Transcripts / Precipio, Inc. (PRPO) · May 18, 2026

Precipio, Inc. (PRPO) Earnings Call Transcript

May 18, 2026

NASDAQ US Health Care Health Care Providers and Services earnings 28 min

Earnings Call Speaker Segments

Ilan Danieli executive
#1

Good afternoon, everyone, and thanks for being with us today for Precipio's Q1 2026 Shareholder Update Call. During this call, we'll go over our financial results, give you an update on operations and commercial progress; and then, for the first time, and after several shareholders asked for it, we're going to open things up for a live Q&A with the audience. Once I finish my remarks, the operator will take over and explain how those who wish to ask a question can do so. Before we review the quarterly financials for Q1, I'd like to pause and step back and talk about where we think the company stands in executing its strategy. At Precipio, our mission is focused on advancing cancer diagnostics and delivering testing solutions to laboratories and clinicians that are faster, more accessible and more actionable. What sets our model apart is that we aren't just developing products in isolation. Because we run our own clinical laboratory, we see real-world diagnostic challenges for ourselves, validate solutions quickly in a clinical setting; and then, after our products have proven their clinical, operational and financial value, we bring them to the broader market. Across the past several quarters, we've kept strengthening both sides of that model. Our pathology business keeps giving us a stable and growing operational foundation while producing cash flow for the company. And our products business along with an expanding commercial infrastructure are putting the company in position for scalable, long-term growth, margin increase and cash generation. Before we get to the numbers, I'd like to pause and talk about a topic several people have brought up, which is the variability and predictability of the company's revenues. Let's break it down by division, beginning with pathology services. Broadly speaking, the pathology services business is fairly predictable. Once a customer is won, they typically have a steady number of patients coming in. A fairly consistent percentage of those patients will need some sort of biopsy, which gets sent to our lab. Testing modalities are pretty standard. We keep costs very well controlled, so there isn't much variance there. The same is true for revenue build, reimbursement and cash collected, all quite predictable. There are 2 elements beyond our control that can cause fluctuations in the division's performance. The first is customer transition. For instance, a physician might retire or the practice might be acquired by a large hospital network that brings testing in-house. When that happens, the flow of patient samples from that customer will stop. The second element, which we saw this quarter, is a change to reimbursement. Every year, usually in January, CMS releases its new fee schedule. Since it's a government organization, there's no negotiating. So the new fee schedule essentially becomes our new pricing. As you can imagine, rate increases are very rare. And typically, it goes the opposite direction. During the first part of Q1 this year, CMS came out with its fresh 2026 fee schedule, and that schedule contained an 8% cut to the reimbursement for flow cytometry, which ranks among the tests we perform most often. Because of that, we ended up recording a revenue write-down of roughly $0.5 million during the quarter, which produced a big swing in net income compared with the previous quarter. So even though neither our customer base nor our patient sample volume shifted, the updated fee schedule from CMS hit our revenue, our net income, and our gross margins. We have several initiatives underway aimed at lowering our operating costs and lifting that margin back up, basically undoing what the fee schedule did. And as you observed, cash flow from operations remained positive; that pretty much sums up what drove the variability in the pathology services business; over on the product side, broadly speaking, once a customer is up and running, the revenue tends to be fairly steady and easy to forecast; during this quarter, revenue came in $80,000 lower than the previous quarter, which happened because one of our largest customers moved its order date from the end of March into early April. So although nothing shifted on the customer side, under revenue recognition principles, naturally, that order will land in Q2 revenue; that is one fairly minor item that can create swings in the products business. The second variable, and the tougher one, is getting customers onboarded. We have talked about this before and shift — accounts ranging from IT obstacles to equipment being down while validations take place. I realize a lot of you have asked about guidance and forecasting, and I genuinely believe that as our customer base expands and we accumulate more experience, we will get better at predicting our future growth. On top of that, a new commercial team is assembling a wider pipeline, which will also give us improved visibility into future growth. I will say more about the pipeline later on this call. Even inside the products business, those swings mostly stem from the initial setup of a customer. And after a customer goes live, there are much fewer fluctuations and revenue becomes easier to predict. So as our customer base grows and we build up more experience. I do believe we will ultimately get to the point where we can get — start feeling more at ease forecasting revenue growth. To sum up, this applies to any business, which faces fluctuations from internal sources, but in our case, more from external ones that are mostly beyond our control; still, they show up more often in the pathology business — pathology services business than in the products business, which is one more reason the products business is where our growth focus lies. With that, let's move on to a review of our financial results for the quarter. Total revenue for Q1 stayed flat versus the prior quarter at $6.71 million and rose more than 30% compared with the same quarter a year ago. On the pathology side, revenue rose slightly more than $6 million during this quarter, compared with $5.9 million in the prior quarter, and it was up 36% versus $4.4 million in Q1 of the prior year. Product revenue fell by $80,000, going from $740,000 to $660,000 in this quarter, with the effect coming from the timing of a customer shipment we had originally anticipated later in the quarter, which shifted into Q2. In accounting terms, that revenue moves between quarters, but from a business perspective, essentially nothing has changed. Even more significantly, this quarter shows ongoing momentum in the areas we consider the best signals of future growth, especially commercial expansion, distributor engagement, and pipeline development, which makes it a foundational quarter for our broader commercial strategy, and I want to spend a few moments walking through those results. As we noted, we recently put money into hiring a dedicated commercial team whose aim is to speed up adoption of our proprietary product portfolio by way of distributor relationships and direct customer engagement. Because of the onboarding and sales cycle that comes with molecular diagnostic products, the team has initially concentrated on relationship building and educating our distribution partners, locating qualified target accounts, and creating a scalable pipeline. That happens through a process that starts mostly with our distributors. As we have said before, our team must first establish relationships with the distributor reps and get them familiar with our company, with our value proposition, and with what we offer.

Ilan Danieli executive
#2

After that takes place, they're able to start sitting down with every rep, going over their territory, and pinpointing potential leads that meet the qualification criteria. Our method for qualifying leads follows a fairly simple path. To start, we confirm the customer already runs cancer diagnostic operations and either performs some of the testing our products could take over internally, or more often, ships it out to a third-party lab. That marks the customer as a suitable target lab. With that settled, we find out which products interest them and what their yearly volumes look like, so we can evaluate and set an estimated yearly dollar revenue figure tied to their current testing volume for our panels. Once that yearly revenue potential figure exists, the account turns into a qualified lead, and we start working alongside the distributor rep to set up an introductory meeting that kicks off the sales process. That effort began when we brought on the commercial team at the beginning of the year, and measurable results are already showing up. In Q1, the commercial team built relationships with roughly 20 new distributor reps, spotted 2 — pardon me, 10 new qualified customer opportunities, and brought about $3 million of annualized revenue potential into the pipeline. Along with opportunities we already had, our commercial pipeline as it stands now accounts for roughly $10 million in annualized revenue potential. Just to be clear, we aren't projecting $10 million in revenue for this year—the timing of each customer's launch remains uncertain. Even so, we view this as evidence of a disciplined, thoughtful method for identifying prospects and developing both a sales funnel and longer-term pipeline. This feels particularly promising given that the sales group came on board just as the year began and initially completed thorough instruction on our technology, the products we offer, conditions in the market, and how we stack up against competitors. Many of these initial outcomes validate the size of the opportunity before us as well as the approach we're taking commercially. Since our team continues to expand the relationships we hold with distributors and convert promising leads into paying accounts, we expect the pipeline to keep expanding and to turn more of it into repeat revenue; let's now turn our attention to margins and profitability. For this quarter, adjusted EBITDA landed at negative $200,000, compared with positive $960,000 during Q4 of 2025 — that's a sizable swing, so I want to take a few minutes to walk through it. The key point is that the bulk of this quarter-over-quarter movement stemmed from a combination of items tied to timing, nonrecurring accounting effects, and the investments we are funding to fuel future growth. Four main drivers accounted for the change in EBITDA from one quarter to the next. To start, as we talked about, during this quarter we felt a hit related to reimbursement stemming from modifications to specific CMS pathology billing codes, and that reduced our gross profit — our gross profit — by about $125,000. Next, the addition of our commercial team cost approximately $250,000 for the quarter. Payroll, travel, business development costs, and marketing efforts are all included in that figure. As we've told you, we have already witnessed commercial gains from bringing these people on board, reflected in pipeline growth. The key point is that we aren't viewing this merely as extra cost — it's an intentional wager on building up the commercial foundation required so that the products side of our business can expand across the coming several years. Put differently, when that team starts bringing in more revenue — say $1 million each quarter — then spending $0.25 million a quarter will clearly have proven worthwhile. Third, during Q4 2025 we got a lift from a onetime, nonrecurring accounting adjustment tied to bonus compensation accrued earlier, and that produced a positive swing of roughly $360,000 in adjusted EBITDA relative to the current quarter. And finally, product gross profit fell by $280,000 because delivery shifted from late Q1 into early Q2, along with lower production volumes. Looking at it from a business activity standpoint, that revenue wasn't actually lost. It just crossed over between reporting periods. Together, these items drove a $1 million swing in EBITDA. But as you're able to see, for the most part these are one-time adjustments, and they involve a significant sum of money, without any relationship to the way the business is run. Let me now move on to gross margins. During the quarter, gross margin for the company was 40%, compared with 47% in Q4. As with EBITDA, we believe it's important to distinguish structural margin pressure from effects that are either temporary or related to investment. The margin contraction in this quarter was primarily driven by the same items we just discussed. Revenue timing, reimbursement changes, and investments in commercial capacity, which are now mostly in place. Beyond that, our Q4 margins got a bit of a boost since we built more product in Q4 than we did in Q1, which happened because we'd already told everyone about the maintenance downtime we anticipated for the equipment. Once output returns to its typical level and growth keeps coming, margins should climb back to the stronger levels that this business's fundamental economics naturally support. Our forward-looking confidence stems from the fact that a large share of these expenses tend to stay fairly constant. That means when revenue rises, especially within the product segment, we see room for the business to deliver substantial operating leverage. Looking at the company as a whole, we anticipate that margins will bounce back once product revenue grows, and eventually they could even surpass what we've seen historically, since an increasing share of our revenue is coming from proprietary offerings and the services tied to those products. Now a quick note on cash flow. We posted roughly negative $40,000 in total cash flow for the quarter, though operating cash flow stayed in positive territory at about $60,000. That dynamic is largely in line with what we've typically experienced during the first quarter, mostly because of annual expense resets at the beginning of the year combined with slower collections tied to patient insurance deductible cycles. So, on the quarter's cash flow — we really don't see it as a sign of any structural shift in the business. It's just normal seasonality, and we'd expect that to even out as the year goes on. With that in mind, there are a few things I'd like to touch on. To start, we're looking for our commercial pipeline to keep growing, and for more of that pipeline to turn into revenue in the back half of the year. After that, we expect margins to improve, since the commercial investments we've been making should begin contributing more meaningfully to revenue growth, and also because production is going up. And overall, we're anticipating better operational results as we move through the remainder of 2026. Even though results for a given quarter may fluctuate due to things like reimbursement patterns, when shipments go out, or seasonal effects, we still believe the overall direction of the business remains strongly positive. We continue to grow where we sell, add more programs to our pipeline, strengthen what our product platform offers, and invest in the infrastructure we see as necessary for building a far larger and more scalable operation in the future. With that, I'll hand it over to the operator so we can take questions. Operator, please go ahead. Thank you. Thanks, Chloe. In the meantime, as we're getting this roster ready, a few questions came in ahead of the call. I'll go through those, and then we can turn to the live Q&A. The first one asked: could you say more about how much your labs are being utilized? Put differently, how much additional revenue could the laboratories you have now bring in with no major CapEx?

Ilan Danieli executive
#3

Right now, our pathology services business runs at roughly $24 million annualized. Depending on the case mix, we think we have laboratory capacity of somewhere between $45 million and $50 million before any changes would be needed that require meaningful CapEx or additional hiring. On the second question: your recent corporate deck has a slide referring to the potential to expand your technology into larger multimillion dollar markets. Is there a defined road map for those expansion plans? And if there is, what additional CapEx and R&D expenses would be involved, and what type of financing? That's a very important question, and it gets right to the heart of how we view Precipio's long-term evolution. At present, our main emphasis stays on execution within the product portfolio we have and the markets we already serve. Even inside our current addressable market, we remain at a very early stage of penetration; for context, our products business brought in just under $3 million of revenue last year. That sits within an annual U.S. TAM of about $0.5 billion. So with the products already in place, we see a very substantial runway for growth. That said, one reason we point to broad market opportunities in our corporate materials is our belief that the underlying platform being built has uses well beyond the hematology-focused offerings we have today. What makes Precipio unique isn't any individual product; it's the model itself — combining a real-world clinical laboratory environment for diagnostic workflows, operational validation capabilities and commercial distribution infrastructure. Over time, we believe this model can be applied to additional areas of diagnostics. That said, we plan to pursue expansion in a disciplined way. Our philosophy is to keep scaling the existing product business, grow recurring revenue, strengthen cash flow generation and leverage the commercial infrastructure we're building now. As the company grows and becomes increasingly well capitalized, we believe we'll be well positioned to selectively move into adjacent markets without necessarily needing the large-scale R&D spending and related capital that traditional diagnostic companies typically require; and I think that distinction matters a great deal, because our development model is tightly integrated with our clinical operations, and we think we can potentially enter new markets with lower development risk, shorter validation cycles and significantly greater capital efficiency than many traditional life sciences companies. So in summary, while we aren't announcing any specific expansion initiatives today, we do believe the long-term opportunity for the platform extends meaningfully beyond the markets we currently serve. All right; with that, Chloe, let's go to our first question.

Adam Hutt analyst
#4

This basically picks up where we left off — you've already addressed these types of questions — but would you be inclined to, say, establish a site in the Midwest or out West? Would logistics rule that out? Or is shipping efficient enough that you'd never require an additional location somewhere else?

Ilan Danieli executive
#5

Adam, thanks, it's nice to hear from you. That's a fair question. My answer would be no. For the most part, logistics work quite well, and there's genuinely no major justification for shelling out that sort of cash to build a second site. Take this example — as you're aware, our lab sits in Connecticut. Even starting from New Jersey, FedEx collects the samples, they pass through Memphis, and they show up the following morning around 9 or 10 a.m. So there's not a real edge even coming from a neighboring state. Having a presence on the West Coast wouldn't bring much of a logistics benefit. So if anything, should we reach that stage, we'd grow our capacity, which is largely tied to the CapEx equipment side, and at those revenue levels, the process is highly efficient.

Adam Hutt analyst
#6

So the footprint grows in New Haven, and there's nothing in Los Angeles — is that right?

Ilan Danieli executive
#7

No, no. That isn't necessary at all.

Adam Hutt analyst
#8

Thanks.

Ilan Danieli executive
#9

OK, Chloe, looks like that was the only question.

Analyst analyst
#10

Ilan, congratulations on the ongoing ramp and the way you're managing cash flow at the company. I suppose you could give us a bit more detail on the ramp, particularly regarding the product side, from Q2 through the remainder of the year? My assumption is that since that order moved into Q2, into April, Q2 will clearly be higher than Q1; and hopefully, with the commercial team you now have in place, we'll see an even stronger loaded back half of the year?

Ilan Danieli executive
#11

Yes. Tom, good to hear from you. And yes, I hope so as well. I believe — the commercial team has likely already made a better-than-expected impact in Q1, as I mentioned, bear in mind, it's only been those 4 months and I'd say at minimum half of that period has gone toward training. So to add roughly $3 million of pipeline is great, and I think that will only grow over time. Naturally, the X factor is how long it takes to convert that $3 million of pipeline into $3 millions of revenue; and that's where it becomes truly difficult because many of those factors are beyond our control. So for instance, we had a customer — I spoke with a customer just this morning, who has finished the validation and is ready to go live from a technical standpoint, what they're waiting on now is arranging a meeting with all the physicians to instruct them on how to order the new test of the system. It sounds mind-numbingly ridiculous, frankly, but those are the things they deal with; and this is a massive organization, so they hold these meetings once a quarter, and that one hasn't been scheduled yet; so this meeting might take place next week, and the customer goes live. This meeting might take place in July and then the customer goes live; so it's really hard to sort of determine what the time line is for these customers to move from readiness to go live and when that turns into revenue. I think the best thing I can offer — efficient; so if the customer says, hey, we want to order $100,000 of products next week, we can deliver that. Unfortunately, we can only control what we can control; so I hope that helps.

Adam Hutt analyst
#12

Let me squeeze in one last question, guys. There's a business I know of, Interpace, which offered a test for pancreatic cancer. The insurance carriers essentially wiped them out. That stock destroyed an enormous amount of wealth. Clearly, with the blood cancers, I believe you can demonstrate far greater efficacy and return per dollar than you could with a pancreas-specific test. Should any of us be worried about the insurance beast that's been something of a bogeyman this quarter?

Ilan Danieli executive
#13

Thanks, Adam. Sure. Whether it keeps me up at night, I can't say, but it's a constant worry, since the payers hold the power and they're the final decision-makers. This isn't your typical supply-and-demand framework. The payers truly control what the revenue will be, or where payments end up. That said, every one of our products, and definitely every one of our services, relies on CPT codes that are well established. I don't know Interpace, but when a company lacks an established CPT code, or has a brand-new code that was only just assigned, a great deal of uncertainty surrounds it. I don't believe that situation applies here. The codes our test uses have been in place for a long time, and they aren't going anywhere. Thousands of pages of clinically validated data back them up. So from that angle, will there be rate fluctuations like the ones we witnessed? Absolutely. As a company, our response has to be operating more efficiently so we hold onto that margin, and that's precisely what we're doing. Still, I don't see a scenario where they come out and say, sure, we've decided to stop testing for acute leukemia and we won't cover it any longer. We won't pay for it anymore. I don't believe that will occur. So all things considered, we're in decent shape.

Adam Hutt analyst
#14

Is there any way to push back — can you take any action regarding how they set the rate — you can. Beyond simply accepting a lower margin internally, what options exist? It's not as if you can go directly to the insurers, right?

Ilan Danieli executive
#15

Correct, that isn't possible. Correct, that isn't possible. So essentially, that's the situation; and typically, we haven't encountered anything outrageous as long as there is clinically supported data. Generally speaking, it tends to remain fairly consistent. And this is essentially the initial decline we've witnessed across 15 years of running the business; it's a drop of 8% affecting one of our tests. That test is run frequently, yet the decline is 8%. So overall, I'd say this is a fairly steady area.

Adam Hutt analyst
#16

Thank you.

Operator operator
#17

All right. That brings us to the end of the Q&A portion, since nobody has anything further to ask. That wraps up the call for today. We appreciate your participation. You're welcome to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Precipio, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Precipio, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.